# Review on Oral Insulin for Diabetics Mellitus

Achal A. Kale, Bilal Sufi, Chandrashekhar M. Deotale, Vaibhav R. Urade

New Montfort Institute of Pharmacy, Wardha, Maharashtra, India

achalkale157@gmail.com

**Abstract:** *Oral insulin is one of the most exciting areas of diabetes therapy, due to the potential benefits of patient convenience, liver rapid insulination, appropriate insulin delivery to avoid hyperinsulin hypertension in the peripheral region, and the potential to avoid the harmful effects of weight gain and low blood sugar. Evidence is growing that early intensive insulin therapy leads to sustainable and tight blood glucose control and leads to serious complications, making effective oral insulin products even more important for the treatment of diabetic patients. Despite the knowledge of this medical need, insulin injections havefailed due to several obstacles. For decades, researchers have tried to develop oral insulin with various technologies, but have not succeeded in clinical and commercial studies. The review summarizes the development status of oral insulin and indicates that it is under clinical trial.*

**Keywords:** alternate routes of insulin delivery oral immunotherapy, diabetes

## REFERENCES

[1]. Bearse MA, Han Y, Schneck ME, Barez S, Jacobsen C, Adams AJ. Local multifocal oscillatory potential abnormalities in diabetes and early diabetic retinopathy. Investig Ophthalmol Vis Sci. 2004;45(9):3259–6

[2]. Hove MN, Kristensen JK, Lauritzen T, Bek T. The prevalence of retinopathy in an unselected population of type 2 diabetes patients from Århus County, Denmark. Acta Ophthalmol Scand. 2004;82(4):443–8.

[3]. Seki M, Tanaka T, Nawa H, Usui T, Fukuchi T, Ikeda K, et al. Early Retinal Neuropathy of Streptozotocin-Induced. Am Diabetes Assoc. 2004;53(September):1–8.

[4]. Huang C, Kim Y, Caramori MLA, Fish AJ, Rich SS, Miller ME, et al. Cellular basis of diabetic nephropathy: II. The transforming growth factor-β system and diabetic nephropathy lesions in type 1 diabetes. Diabetes. 2002;51(12):3577–81.

[5]. Saely CH, Aczel S, Marte T, Langer P, Drexel H. Cardiovascular complications in Type 2 diabetes mellitus depend on the coronary angiographic state rather than on the diabetic state [5]. Diabetologia. 2004;47(1):145–6.

[6]. J, Smith DG, Sullivan K, Hayes S, et al. Incidence of falls, risk factors for falls, and fallrelated fractures in individuals with diabetes and a prior foot ulcer. Diabetes Care. 2002;25(11):1983–6

[7]. Bastaki S. Diabetes mellitus and its treatment. Int J Diabetes Metab. 2005;13(3):111– 34.

[8]. Whiting DR, Guariguata L, Weil C, Shaw J. IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030.

[9]. Diabetes DOF. General aspects of diabetes mellitus. 2014;126.

[10]. Zimmet P. Globalization, coca-colonization and the chronic disease epidemic: Can the Doomsday scenario be averted? J Intern Med Suppl. 2001;249(741):301–10

[11]. Estimates for the year 2000 and projections for 2030. 2004;27(5)

[12]. 12. Ramachandran A, Wan Ma RC, Snehalatha C. Diabetes in Asia. Lancet [Internet]. 2010;375(9712):408–18. Available from: http://dx.doi.org/10.1016/S0140- 6736(09)60937-5

[13]. . Aubert RE. Prevalence, numerical estimates, and projections. 2000;21(9):1414–31.

[14]. Srivastava AK. Diabetes mellitus : Complications and therapeutics Diabetes mellitus : Complications and therapeutics. 2014;(August 2006).

[15]. Kaveeshwar SA, Cornwall J. The current state of diabetes mellitus in India. Australas Med J. 2014;7(1):45–8.

[16]. Giriraj KG, Giriraj KT. Oral Insulin-Fact or Fiction. Resonance 38–43 (2003). Gowthamarajan K, Kulkarni GT. Oral Insulin – Fact or Fiction

**[17].** Gemmil CL. The Greek concept of diabetes. Bull N Y Acad Med. 1972;48:1033-6.

**[18].** Bliss M. The history of insulin. Diabetes Care. 1993;16(3):4-7

**[19].** Uianzon CC, Cheikh I. History of Insulin. J Commu Hospital Internal Med Pers 2012;2(2):1-3

**[20].** Joshi SR, Parikh RM, Das AK. Insulin History, Biochemistry, Physiology and Pharmacology. Supplement Japi. 2007;55:19-21

**[21].** Meier JJ, Holst JJ, Schmidt WE, Nauck MA. Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans. Am J Physiol Endocrinol Metab. 2007

**[22].** Eaton RP, Allen RC, Schade DS. Hepatic removal of insulin in normal man: dose response to endogenous insulin secretion. J Clin Endocrinol Metab 1983

**[23].** Meistas MT, Rendell M, Margolis S, Kowarski AA. Estimation of the secretion rate of insulin from the urinary excretion rate of C-peptide. Study in obese and diabetic subjects.

**[24].** Satake S, Moore MC, Igawa K, Converse M, Farmer B, Neal DW, Cherrington AD. Direct and indirect effects of insulin on glucose uptake and storage by the liver. Diabetes. 2002

**[25].** Curtis ,L.T, Charles A.R, 2ND ,William, pharmacotherapy: A pathophysiology

**[26].** Approach 7 th edtion , Mc Graw Hill -2009

**[27].** Baynest HW. Classification, Pathophysiology, Diagnosis and Management of Diabetes Mellitus. J Diabetes Metab. 2015;06(05):1–10.

**[28].** Katsarou A, Gudbjörnsdottir S, Rawshani A, Dabelea D, Bonifacio E, Anderson BJ, et al. Type 1 diabetes mellitus. Nat Rev Dis Prim [Internet]. 2017;3:1–18. Available from: http://dx.doi.org/10.1038/nrdp.2017.16

**[29].** Leslie RD. Predicting adult-onset autoimmune diabetes clarity from complexity. Diabetes. 2010;59(2):330–1.

**[30].** Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet [Internet]. 2014;383(9911):69–82. Available from: http://dx.doi.org/10.1016/S0140-6736(13)60591-7

**[31].** Buzzetti R, Quattrocchi CC, Nisticò L. Dissecting the genetics of type 1 diabetes: Relevance for familial clustering and differences in incidence. Diabetes Metab Rev. 1998;14(2):111–28.